Secondary offerings announced by drug developers accounted for more than 60% of the stock sales disclosed by all Bay Area public companies in the fourth quarter.
Read More from Bizjournals.com Feed (2025-02-17 17:26:56)
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stock
